Genedata and Titian Software today announced their technology partnership to create an automated, off-the-shelf solution for small molecule and biological inventory management and advanced screening data analysis. Their combined solution integrates Titian Mosaic SampleBank with Genedata Screener® to give screening scientists a best-in-class, streamlined process from plate ordering to data analysis.
Best-in-Class Operational Efficiency for Any Size Pharma or CRO
Scientists can now choose both Genedata Screener’s accelerated data analysis and Mosaic SampleBank’s best practice inventory tracking and management with the confidence that the solutions work together seamlessly. This combination of applications provides a single workflow from sample to screening results, removing many time-consuming steps. Mosaic SampleBank manages the samples from registration through to the creation of assay-ready plates. Once screened, resulting data are directly analyzed on the Genedata Screener platform, which automates the entire workflow from raw data to activity, potency, selectivity, and toxicity results. The integrated solutions:
• decrease overall system implementation costs
• create workflow efficiencies by eliminating time-consuming process steps
• reduce errors by removal of manual file handling
• advance best practices as best-in-class solutions
“Genedata and Titian customers now have the best of both worlds in one easy-to-use solution,” said Edmund Wilson, CEO of Titian Software. “Specifically, plate information is automatically transferred from Mosaic SampleBank to Genedata Screener for analysis. The integration eliminates manual file handling and this heightened level of automation generates new operational efficiencies that lower costs, improve productivity, and most importantly – enhance life science research.”
“Our collaboration with Titian not only creates a streamlined process for plate ordering and data analysis, it also gives budget-conscious screening labs a single, end-to-end solution that reduces overhead without compromising on world-class technology,” noted Dr. Othmar Pfannes, CEO of Genedata. “Genedata is dedicated to partnering with companies such as Titian that raise the bar on automating workflows in the drug discovery process.”
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
About Titian Software
Founded in 1999, Titian Software supplies software and consultancy to improve sample management and inventory logistics for life science research. Mosaic is Titian’s customizable, modular software to control and monitor all aspects of sample storage and preparation for compounds, reagents and biologics. Companies worldwide, from small biotech to global pharma, trust Mosaic to provide a seamless, error-free sample supply chain. SampleBank and FreezerManagement provide optimized and pre-configured subsets of Mosaic available for rapid deployment.
Follow Titian Software on LinkedIn
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.